Adhera Therapeutics, Inc. – OTC:ATRX

Add to watchlist

Market closed

Open in 3 days

-100.00%

month

-100.00%

quarter

-100.00%

year

Market Cap	2.27M
Enterprise value	2.48M

P/E	-0.47
EV/Sales	N/A
EV/EBITDA	4.06
Price/Sales	N/A
Price/Book	-0.05
PEG ratio	N/A
EPS	-0.51

Revenue	N/A
EBITDA	-1.73M
Income	-2.52M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Adhera Therapeutics, Inc. (OTC:ATRX): Profit margin
Dec 2022	0	1.62M
Mar 2023	0	-886K
Jun 2023	0	271K
Sep 2023	0	-3.53M

Adhera Therapeutics, Inc. (OTC:ATRX): Payout ratio
Payout ratio	0%

Adhera Therapeutics, Inc. (OTC:ATRX): Dividend Yield
2018	35.06%
2019	231.38%
2020	341.18%
2021	225.65%
2022

Adhera Therapeutics, Inc. (OTC:ATRX): Debt to assets
Dec 2022	79000	22.26M	28183.54%
Mar 2023	104000	23.19M	22304.81%
Jun 2023	82000	22.86M	27889.02%
Sep 2023	44074	26.35M	59807.4%

Adhera Therapeutics, Inc. (OTC:ATRX): Cash Flow
Dec 2022	-153K	52K
Mar 2023	-310K	347K
Jun 2023	-316K	305K
Sep 2023	-29.15K	3.78K

Adhera Therapeutics alternative data

Adhera Therapeutics, Inc. (OTC:ATRX): Employee count
Aug 2023	2
Sep 2023	2
Oct 2023	2
Nov 2023	2
Dec 2023	2
Jan 2024	2
Feb 2024	2
Mar 2024	2
Apr 2024	2
May 2024	2
Jun 2024	2
Jul 2024	2

Adhera Therapeutics
Hedge Funds Holdings Q1 2023

0.04% 0.00%

of ATRX is owned by hedge funds

1 +0

hedge funds hold ATRX stock

1 +0

shares is hold by hedge funds

ATRX hedge funds holdings changes

Adhera Therapeutics
Insider Trading

Adhera Therapeutics, Inc. (OTC:ATRX): Insider trades (number of shares)
Period	Buy	Sel
Apr 2018	2564627	0
Jul 2018	300040	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	12 Jul 2018	MOSCATO ROBERT JR. director, officer: Chief Executive Offi.. director, officer: Chief Execut..	Series F Convertible Preferred Stock	40	$0.5	$20
Purchase	12 Jul 2018	MOSCATO ROBERT JR. director, officer: Chief Executive Offi.. director, officer: Chief Execut..	Warrants to Purchase Common Stock	300,000	N/A	N/A
Purchase	16 Apr 2018	TRIEU VUONG director, 10 percent owner director, 10 percent owner	Series E Convertible Preferred Stock	162	N/A	N/A
Purchase	16 Apr 2018	TRIEU VUONG director, 10 percent owner director, 10 percent owner	Warrants to Purchase Common Stock	2,564,465	N/A	N/A
Purchase	9 Jun 2017	TRIEU VUONG director, 10 percent owner director, 10 percent owner	Common Stock	10,000	$0.39	$3,900
Purchase	8 Jun 2017	TRIEU VUONG director, 10 percent owner director, 10 percent owner	Common Stock	20,000	$0.39	$7,800
Purchase	7 Jun 2017	TRIEU VUONG director, 10 percent owner director, 10 percent owner	Common Stock	2,500	$0.38	$950
Purchase	7 Apr 2017	RAMELLI JOSEPH W. other: Former Chief Executive Officer other: Former Chief Executive O..	Common Stock	22,500	$0.43	$9,563
Purchase	6 Apr 2017	RAMELLI JOSEPH W. other: Former Chief Executive Officer other: Former Chief Executive O..	Common Stock	13,000	$0.34	$4,368
Purchase	5 Apr 2017	RAMELLI JOSEPH W. other: Former Chief Executive Officer other: Former Chief Executive O..	Common Stock	97,550	$0.31	$30,436

ATRX insider trading transactions

Adhera Therapeutics
Executives

Insider	Age	Since	Compensation
Mr. Andrew Albert Kucharchuk (1981) Chief Executive Officer & Chairman	44		$124,140

Frequently Asked Questions (FAQ)

What's the price of Adhera Therapeutics stock today?

One share of Adhera Therapeutics stock can currently be purchased for approximately $0.
When is Adhera Therapeutics's next earnings date?

Unfortunately, Adhera Therapeutics's (ATRX) next earnings date is currently unknown.
Does Adhera Therapeutics pay dividends?

No, Adhera Therapeutics does not pay dividends.
How much money does Adhera Therapeutics make?

Adhera Therapeutics has a market capitalization of 2.27M.
What is Adhera Therapeutics's stock symbol?

Adhera Therapeutics, Inc. is traded on the OTC under the ticker symbol "ATRX".
What is Adhera Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Adhera Therapeutics?

Shares of Adhera Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Adhera Therapeutics's key executives?
Adhera Therapeutics's management team includes the following people:
- Mr. Andrew Albert Kucharchuk Chief Executive Officer & Chairman(age: 44, pay: $124,140)
How many employees does Adhera Therapeutics have?

As Jul 2024, Adhera Therapeutics employs 2 workers.
When Adhera Therapeutics went public?

Adhera Therapeutics, Inc. is publicly traded company for more then 31 years since IPO on 15 Apr 1994.
What is Adhera Therapeutics's official website?

The official website for Adhera Therapeutics is adherathera.com.
Where are Adhera Therapeutics's headquarters?

Adhera Therapeutics is headquartered at PO Box 2161, Wake Forest, NC.
How can i contact Adhera Therapeutics?

Adhera Therapeutics's mailing address is PO Box 2161, Wake Forest, NC and company can be reached via phone at +91 95183748.

Adhera Therapeutics, Inc.

adherathera.com

Exchange:

OTC

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Adhera Therapeutics, Inc. focuses on the discovery and development of drugs. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.

+91 95183748

PO Box 2161
Wake Forest, NC 70820

CIK: 0000737207
ISIN: US00687E1091
CUSIP: 00687E109